Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 1, 2026Reported sale · Form 4Epperly Melissa B, · $607.9KOpen the filing ↗
- Oct 1, 2026Reported sale · Form 4Epperly Melissa B, · $32.9KOpen the filing ↗
- Sep 30, 2026Reported sale · Form 4Eric Venker, President & Immunovant CEO · $7.3MOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record95918 flagged findings
Reported transactions (Form 4)80since Dec 23, 2025 · and 11 other holdings
Corporate events (8-K)24since Oct 1, 2021
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-20share offering or dilution eventrecentOpen filing ↗“…the purchase of one of the Company’s common shares, which were held by MAAC’s shareholders at an exercise price of $ 11.50 (the…”
+1 more passage from the same document
- “…common shares, which were held by MAAC’s shareholders at an exercise price of $ 11.50 (the “Public Warrants” and, together with…”
- 2026-05-20capital return (buybacks/dividends)recentOpen filing ↗“…for one or more strategic transactions, including acquisitions of companies, asset purchases or the in-licensing of product…”
+1 more passage from the same document
- “…Repurchases of Equity Securities During the three and twelve months ended March 31, 2026, we repurchased 3,956,362 and…”
- 2026-03-03capital return (buybacks/dividends)recentOpen filing ↗“…shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after…”
+1 more passage from the same document
- “…common shares, general business, macroeconomic and market conditions and other investment opportunities. Under the repurchase…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 959)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 5, 26Form 4 ↗Insider transaction
- Oct 5, 26SCHEDULE 13D/A ↗Stake with intent to influence · amendment
- Sep 30, 26Form 144 ↗Notice of proposed sale
- Sep 18, 268-K ↗Current report · Shareholder vote results
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Sep 15, 26Form 144 ↗Notice of proposed sale
- Sep 15, 26Form 144 ↗Notice of proposed sale
959 filings on record, the oldest from Mar 16, 15.
Listing the 25 most recent filings of the 959 on record.
159
- Mar 23, 26Entered a material agreement+1 more in the same filing8-K/A 1.01 ↗
- Mar 3, 26Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Mar 20, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Feb 21, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Oct 28, 24A material agreement was terminated+2 more in the same filing8-K 1.02 ↗
- Sep 23, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- May 30, 24Entered a material agreement8-K 1.01 ↗
- Dec 14, 23Completed an acquisition or disposal+2 more in the same filing8-K 2.01 ↗
- Oct 23, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Sep 29, 23Entered a material agreement+1 more in the same filing8-K 1.01 ↗
3 senior executive changes2023show all 3hide
- Aug 4, 23A senior executive left or was appointed8-K 5.02 ↗
- Mar 16, 23A senior executive left or was appointed8-K 5.02 ↗
- Feb 21, 23A senior executive left or was appointed8-K 5.02 ↗
- Feb 7, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
6 older filings not shown
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- FMR LLC10.3%Feb 27, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Morgan Stanley5.7%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
- QVT Financial LP4.3%Jun 30, 25SCHEDULE 13G/A ↗
- Ramaswamy Vivek3.6%Mar 31, 26SCHEDULE 13G/A ↗1 earlier filing
- VIKING GLOBAL INVESTORS LP3.4%Sep 30, 25SCHEDULE 13G/A ↗13 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
show one more holderhide
- SB Investment Advisers (UK) Limited2.3%Dec 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Sep 30, Venker Eric filed notice of intent to sell up to $7.3M. That is about 0.03% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $7.3M on Sep 30, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+9 more recent notices · 9 with a later sale
- Oct 1, 26Sell$608KEpperly Melissa B,↗
- Oct 1, 26Sell$33KEpperly Melissa B,↗
- Sep 30, 26Sell$7.3MEric VenkerPresident & Immunovant CEO↗
- Sep 15, 26Sell$187KMeghan Fitzgerald↗
- Sep 15, 26Sell$16KMeghan Fitzgerald↗
- Sep 15, 26Sell$172KEpperly Melissa B,↗
- Sep 15, 26Sell$24KEpperly Melissa B,↗
- Sep 8, 26Sell$798KMeghan Fitzgerald↗
- Aug 28, 26Sell$5.9MEric VenkerPresident & Immunovant CEO↗
- Aug 28, 26Sell$1.2MEric VenkerPresident & Immunovant CEO↗
- Aug 21, 26Sell$5.3MMayukh SukhatmePresident & CIO↗
- Aug 20, 26Sell$653KMayukh SukhatmePresident & CIO↗
There are 2 more transactions in this stretch.
Stock compensation, tax and giftsshow the 26 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 1, 26Compensation$79KEpperly Melissa B,↗
- Sep 30, 26Tax$1.5MFrank TortiPresident and Vant Chair↗
- Sep 30, 26Tax$2.8MMatthew GlineCEO↗
- Sep 30, 26Compensation$770KEric VenkerPresident & Immunovant CEO↗
- Sep 30, 26Tax$1.7MMayukh SukhatmePresident & CIO↗
- Sep 20, 26Tax$154KJennifer HumesChief Accounting Officer↗
- Sep 20, 26Tax$85KRichard PulikCFO↗
- Sep 16, 26Compensationamount n/aKEITH S MANCHESTER↗
- Sep 16, 26Compensationamount n/aJAMES C MOMTAZEE↗
- Sep 16, 26Compensationamount n/aMeghan Fitzgerald↗
- Sep 16, 26Compensationamount n/aIlan Oren↗
- Sep 16, 26Compensationamount n/aDaniel Allen Gold↗
- Sep 16, 26Compensationamount n/aEpperly Melissa B,↗
- Sep 10, 26Tax$210KDaniel Allen Gold↗
- Sep 10, 26Tax$119KJAMES C MOMTAZEE↗
- Sep 10, 26Tax$71KMeghan Fitzgerald↗
- Sep 10, 26Tax$97KIlan Oren↗
- Sep 10, 26Tax$89KEpperly Melissa B,↗
- Sep 8, 26Compensation$176KMeghan Fitzgerald↗
- Aug 28, 26Compensation$770KEric VenkerPresident & Immunovant CEO↗
- Aug 21, 26Compensation$557KMayukh SukhatmePresident & CIO↗
- Aug 20, 26Compensation$67KMayukh SukhatmePresident & CIO↗
- Aug 20, 26Tax$512KEric VenkerPresident & Immunovant CEO↗
- Aug 20, 26Tax$212KRichard PulikCFO↗
- Aug 19, 26Compensation$666KMayukh SukhatmePresident & CIO↗
- Aug 18, 26Compensation$405KMayukh SukhatmePresident & CIO↗
The full record holds 664 transactions and goes back to Oct 16, 22.
Its sector and its market
Roivant Sciences Ltd among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Roivant Sciences Ltd, the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Roivant Sciences Ltd in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 959 documents on file, from Mar 16, 2015 to Oct 5, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.